295 related articles for article (PubMed ID: 18199797)
1. Sirolimus reduces polycystic liver volume in ADPKD patients.
Qian Q; Du H; King BF; Kumar S; Dean PG; Cosio FG; Torres VE
J Am Soc Nephrol; 2008 Mar; 19(3):631-8. PubMed ID: 18199797
[TBL] [Abstract][Full Text] [Related]
2. Effect of Sirolimus on Native Total Kidney Volume After Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Pilot Study.
Davis S; Gralla J; Chan L; Wiseman A; Edelstein CL
Transplant Proc; 2018 Jun; 50(5):1243-1248. PubMed ID: 29880342
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
[TBL] [Abstract][Full Text] [Related]
6. Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial.
Riegersperger M; Herkner H; Sunder-Plassmann G
Trials; 2015 Apr; 16():182. PubMed ID: 25899445
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus therapy to halt the progression of ADPKD.
Perico N; Antiga L; Caroli A; Ruggenenti P; Fasolini G; Cafaro M; Ondei P; Rubis N; Diadei O; Gherardi G; Prandini S; Panozo A; Bravo RF; Carminati S; De Leon FR; Gaspari F; Cortinovis M; Motterlini N; Ene-Iordache B; Remuzzi A; Remuzzi G
J Am Soc Nephrol; 2010 Jun; 21(6):1031-40. PubMed ID: 20466742
[TBL] [Abstract][Full Text] [Related]
8. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP
J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726
[TBL] [Abstract][Full Text] [Related]
9. [Autosomal dominant polycystic kidney disease (ADPKD): rapamycin as a new treatment option].
Serra AL; Wüthrich RP
Praxis (Bern 1994); 2009 Dec; 98(25):1511-6. PubMed ID: 20013687
[TBL] [Abstract][Full Text] [Related]
10. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Wüthrich RP; Kistler AD; Serra AL
Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
[TBL] [Abstract][Full Text] [Related]
11. Randomized intervention studies in human polycystic kidney and liver disease.
Schrier RW
J Am Soc Nephrol; 2010 Jun; 21(6):891-3. PubMed ID: 20431043
[No Abstract] [Full Text] [Related]
12. Sirolimus for treatment of autosomal-dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
Liu YM; Shao YQ; He Q
Transplant Proc; 2014; 46(1):66-74. PubMed ID: 24507028
[TBL] [Abstract][Full Text] [Related]
13. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH;
Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment.
Soliman A; Zamil S; Lotfy A; Ismail E
Transplant Proc; 2012 Dec; 44(10):2936-9. PubMed ID: 23195001
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.
Stallone G; Infante B; Grandaliano G; Bristogiannis C; Macarini L; Mezzopane D; Bruno F; Montemurno E; Schirinzi A; Sabbatini M; Pisani A; Tataranni T; Schena FP; Gesualdo L
Nephrol Dial Transplant; 2012 Sep; 27(9):3560-7. PubMed ID: 22785114
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?
Canaud G; Knebelmann B; Harris PC; Vrtovsnik F; Correas JM; Pallet N; Heyer CM; Letavernier E; Bienaimé F; Thervet E; Martinez F; Terzi F; Legendre C
Am J Transplant; 2010 Jul; 10(7):1701-6. PubMed ID: 20642692
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin analogues for treatment of polycystic liver disease.
Gevers TJ; Drenth JP
Curr Opin Gastroenterol; 2011 May; 27(3):294-300. PubMed ID: 21191289
[TBL] [Abstract][Full Text] [Related]
18. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
[TBL] [Abstract][Full Text] [Related]
19. Everolimus in patients with autosomal dominant polycystic kidney disease.
Walz G; Budde K; Mannaa M; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hörl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Büchert M; May C; Gschaidmeier H; Kramer S; Eckardt KU
N Engl J Med; 2010 Aug; 363(9):830-40. PubMed ID: 20581392
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.
Renken C; Fischer DC; Kundt G; Gretz N; Haffner D
Nephrol Dial Transplant; 2011 Jan; 26(1):92-100. PubMed ID: 20615907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]